

OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>HAIGHT NELSON M</u> <hr/> (Last) (First) (Middle) <u>BIOCITY GLASGOW BO'NESS ROAD</u> <u>NEWHOUSE LANARKSHIRE</u> <hr/> (Street) <u>MOTHERWELL X0 ML1 5UH</u> <u>LANARKSHIRE</u> <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 03/18/2026	3. Issuer Name and Ticker or Trading Symbol <u>Virax Biolabs Group Ltd [VRAX]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Options (right to buy)	(1)	11/17/2032	Ordinary Shares	2,000	15.4	D	
Stock Options (right to buy)	(2)	04/18/2033	Ordinary Shares	10,000	6	D	
Stock Options (right to buy)	(3)	04/18/2034	Ordinary Shares	10,000	0.68	D	
Stock Options (right to buy)	(4)	04/08/2035	Ordinary Shares	10,000	0.88	D	

Explanation of Responses:

- On November 17, 2022, the Company granted 2,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal halves on November 17 of each of 2023 and 2024. The vested portions of such options will become exercisable upon vesting.
- On April 18, 2023, the Company granted 10,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal halves on April 18 of each of 2024 and 2025. The vested portions of such options will become exercisable upon vesting.
- On April 18, 2024, the Company granted 10,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal thirds on April 18 of each of 2025, 2026 and 2027. The vested portions of such options will become exercisable upon vesting.
- On April 8, 2025, the Company granted 10,000 stock options under the Company's 2024 Equity Incentive Plan. The options vest in equal thirds on April 8 of each of 2026, 2027 and 2028. The vested portions of such options will become exercisable upon vesting.

/s/ Nelson Haight

03/31/2026

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.